Incyte (INCY) Receivables - Other (2011)

Incyte (INCY) reported Receivables - Other of $19.0 million for Q4 2011.

Incyte (INCY) Receivables - Other (2011) Analysis & Trends

Incyte has reported Receivables - Other for 1 years, with the latest figure at $19.0 million in Q4 2011.

For the quarter ending Q4 2011, Receivables - Other changed N/A year-over-year to $19.0 million; the trailing twelve-month figure through Dec 2011 stood at $19.0 million (changed N/A YoY), and the FY2011 full-year result was $19.0 million, changed N/A from the prior year.
Receivables - Other for Q4 2011 stood at $19.0 million.
The five-year high for Receivables - Other was $19.0 million in Q4 2011, with the low at $19.0 million in Q4 2011.

Peer Comparison

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)
1	Alterity Therapeutics	925,601.88 Bn	925,601.85 Bn	-
2	Belite Bio	58,560.00 Bn	58,560.00 Bn	-
3	Quantum Biopharma	17,284.41 Bn	17,284.40 Bn	-
4	Legend Biotech	2,809.00 Bn	2,808.71 Bn	242.10 Mn
5	Evaxion A	1,334.43 Bn	1,334.42 Bn	-
6	Akari Therapeutics	1,312.27 Bn	1,312.26 Bn	-
7	Psyence Biomedical	212.16 Bn	212.16 Bn	-
8	Vertex Pharmaceuticals	114.83 Bn	107.58 Bn	2.59 Bn
9	Abivax	91.96 Bn	91.96 Bn	-
10	Incyte	19.62 Bn	15.60 Bn	1.17 Bn

Historic Data

Download Data

Date	Value
Dec 31, 2011	19.00 Mn
Dec 31, 2011	19.00 Mn